137 related articles for article (PubMed ID: 10449972)
21. Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective.
Sakorafas GH; Tsiotou AG; Tsiotos GG
Cancer Treat Rev; 2000 Feb; 26(1):29-52. PubMed ID: 10660490
[TBL] [Abstract][Full Text] [Related]
22. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of transforming growth factor beta receptors in human pancreatic adenocarcinoma.
Venkatasubbarao K; Ahmed MM; Mohiuddin M; Swiderski C; Lee E; Gower WR; Salhab KF; McGrath P; Strodel W; Freeman JW
Anticancer Res; 2000; 20(1A):43-51. PubMed ID: 10769633
[TBL] [Abstract][Full Text] [Related]
24. Molecular genetics of malignant insulinoma.
Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
[TBL] [Abstract][Full Text] [Related]
25. Molecular prognostic markers in pancreatic cancer.
Ghaneh P; Kawesha A; Evans JD; Neoptolemos JP
J Hepatobiliary Pancreat Surg; 2002; 9(1):1-11. PubMed ID: 12021893
[TBL] [Abstract][Full Text] [Related]
26. Growth factors and oncogenes in human gastrointestinal carcinomas.
Tahara E
J Cancer Res Clin Oncol; 1990; 116(2):121-31. PubMed ID: 2157713
[TBL] [Abstract][Full Text] [Related]
27. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation.
Ellenrieder V; Hendler SF; Boeck W; Seufferlein T; Menke A; Ruhland C; Adler G; Gress TM
Cancer Res; 2001 May; 61(10):4222-8. PubMed ID: 11358848
[TBL] [Abstract][Full Text] [Related]
28. Role of growth factors in pancreatic cancer.
Korc M
Surg Oncol Clin N Am; 1998 Jan; 7(1):25-41. PubMed ID: 9443985
[TBL] [Abstract][Full Text] [Related]
29. The Smad family and its role in pancreatic cancer.
Singh P; Wig JD; Srinivasan R
Indian J Cancer; 2011; 48(3):351-60. PubMed ID: 21921337
[TBL] [Abstract][Full Text] [Related]
30. Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo.
Kleeff J; Maruyama H; Ishiwata T; Sawhney H; Friess H; Büchler MW; Korc M
Gastroenterology; 1999 May; 116(5):1202-16. PubMed ID: 10220513
[TBL] [Abstract][Full Text] [Related]
31. Characterization of a newly established human pancreatic carcinoma cell line, UK Pan-1.
Fralix KD; Ahmed MM; Mattingly C; Swiderski C; McGrath PC; Venkatasubbarao K; Kamada N; Mohiuddin M; Strodel WE; Freeman JW
Cancer; 2000 May; 88(9):2010-21. PubMed ID: 10813711
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of protein tyrosine kinases attenuates increases in expression of transforming growth factor-beta isoforms and their receptors following arterial injury.
Ward MR; Agrotis A; Kanellakis P; Dilley R; Jennings G; Bobik A
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2461-70. PubMed ID: 9409216
[TBL] [Abstract][Full Text] [Related]
33. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
[TBL] [Abstract][Full Text] [Related]
34. TGFbeta1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation.
Giehl K; Seidel B; Gierschik P; Adler G; Menke A
Oncogene; 2000 Sep; 19(39):4531-41. PubMed ID: 11002426
[TBL] [Abstract][Full Text] [Related]
35. Transforming growth factor β and Ras/MEK/ERK signaling regulate the expression level of a novel tumor suppressor Lefty.
Miyata N; Azuma T; Hozawa S; Higuchi H; Yokoyama A; Kabashima A; Igarashi T; Saeki K; Hibi T
Pancreas; 2012 Jul; 41(5):745-52. PubMed ID: 22441145
[TBL] [Abstract][Full Text] [Related]
36. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.
Wang D; Kanuma T; Mizunuma H; Takama F; Ibuki Y; Wake N; Mogi A; Shitara Y; Takenoshita S
Cancer Res; 2000 Aug; 60(16):4507-12. PubMed ID: 10969799
[TBL] [Abstract][Full Text] [Related]
37. Molecular biomarkers for progression of intraductal papillary mucinous neoplasm of the pancreas.
Kuboki Y; Shimizu K; Hatori T; Yamamoto M; Shibata N; Shiratori K; Furukawa T
Pancreas; 2015 Mar; 44(2):227-35. PubMed ID: 25423558
[TBL] [Abstract][Full Text] [Related]
38. Ras- and Raf-mediated regulation of transforming growth factor beta 1 gene expression by ligands of tyrosine kinase receptors in PC12 cells.
Cosgaya JM; Aranda A
Oncogene; 1996 Jun; 12(12):2651-60. PubMed ID: 8700524
[TBL] [Abstract][Full Text] [Related]
39. Transforming growth factor beta 1 selectively increases gene expression of the serine/threonine kinase receptor 1 (SKR1) in human hepatoma cell lines.
Inagaki M; Wang Z; Carr BI
Cell Struct Funct; 1994 Oct; 19(5):305-13. PubMed ID: 7850892
[TBL] [Abstract][Full Text] [Related]
40. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
